Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maher Hanoun

Showing results (41-50 of 48) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 48 results.
Journal of Hematology & Oncology|September 5, 2022
Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantationDesiree Kunadt, Sebastian Stasik, Klaus H Metzeler, et al.
American Journal of Hematology|January 6, 2026
Randomized Comparison of Cardiotoxicity With 60 Versus 90 mg Daunorubicin in AML Induction TherapyStefan Markus Dendorfer, Katharina Schmidt-Brücken, Michael Kramer, et al.
Cancer Cell|October 24, 2025
RAF-independent MEK mutations drive refractory histiocytic neoplasms but respond to ERK inhibitionEli L Diamond, Jean-Francois Emile, Takeshi Fujino, et al.
Blood Cancer Journal|October 5, 2021
Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemiaChristina Rautenberg, Friedrich Stölzel, Christoph Röllig, et al.
Blood Advances|November 6, 2024
Validation of the revised 2022 European LeukemiaNet risk stratification in adult patients with acute myeloid leukemiaLeo Ruhnke, Marius Bill, Sven Zukunft, et al.
Leukemia|July 21, 2025
Gemtuzumab ozogamicin in first-line treatment of CBF-AML: insights from a retrospective multi-center analysisJulian Ronnacker, Philippe J Muller, Jan-Henrik Mikesch, et al.
Haematologica|June 9, 2022
Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4Sabine Kayser, David Martínez-Cuadrón, Maher Hanoun, et al.
Leukemia|October 28, 2025
Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patientsMarius Bill, Jan-Niklas Eckardt, Konstanze Döhner, et al.
Pageof 5

Showing results (41-50 of 48) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
Journal of Hematology & Oncology|September 5, 2022
Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantationDesiree Kunadt, Sebastian Stasik, Klaus H Metzeler, et al.
American Journal of Hematology|January 6, 2026
Randomized Comparison of Cardiotoxicity With 60 Versus 90 mg Daunorubicin in AML Induction TherapyStefan Markus Dendorfer, Katharina Schmidt-Brücken, Michael Kramer, et al.
Cancer Cell|October 24, 2025
RAF-independent MEK mutations drive refractory histiocytic neoplasms but respond to ERK inhibitionEli L Diamond, Jean-Francois Emile, Takeshi Fujino, et al.
Blood Cancer Journal|October 5, 2021
Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemiaChristina Rautenberg, Friedrich Stölzel, Christoph Röllig, et al.
Blood Advances|November 6, 2024
Validation of the revised 2022 European LeukemiaNet risk stratification in adult patients with acute myeloid leukemiaLeo Ruhnke, Marius Bill, Sven Zukunft, et al.
Leukemia|July 21, 2025
Gemtuzumab ozogamicin in first-line treatment of CBF-AML: insights from a retrospective multi-center analysisJulian Ronnacker, Philippe J Muller, Jan-Henrik Mikesch, et al.
Haematologica|June 9, 2022
Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4Sabine Kayser, David Martínez-Cuadrón, Maher Hanoun, et al.
Leukemia|October 28, 2025
Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patientsMarius Bill, Jan-Niklas Eckardt, Konstanze Döhner, et al.
Pageof 5